预约演示
更新于：2025-09-16
Fluticasone propionate/Salmeterol xinafoate
丙酸氟替卡松/昔萘酸沙美特罗
更新于：2025-09-16
概要
基本信息
药物类型 小分子化药 |
别名 Salmeterol Xinafoate/Fluticasone Propionate、Salmeterol/Fluticasone Propionate、Synflutide + [33] |
作用方式 激动剂 |
作用机制 GR激动剂(糖皮质激素受体激动剂)、cPLA2α 激动剂(胞内磷脂酶A2 激动剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
查看全部结构式(2)
关联
322
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床试验CTR20252183
沙美特罗替卡松吸入粉雾剂在中国成年健康受试者中的一项单中心、随机、开放、空腹单次给药生物等效性试验
CTR20244821
沙美特罗替卡松粉吸入剂在健康人空腹状态下的生物等效性试验
NCT06676319
A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的专利（医药）
登录后查看更多信息
691
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的文献（医药）2025-10-01INTERNATIONAL IMMUNOPHARMACOLOGY
5-aminolaevulinic acid combined with sodium ferrous citrate ameliorated collagen-induced arthritis via anti-inflammatory effects and fibroblast-like synoviocytes-driven B cell immunomodulation
Article
作者: Fujino, Masayuki ; Nakajima, Motowo ; Kamiya, Atsuko ; Ito, Hidenori ; Ma, Kuai ; Takahashi, Kiwamu ; Wang, Chunsheng ; Ding, Zhaolun ; Li, Xiao-Kang
PURPOSE:
This study evaluated the therapeutic potential of 5-aminolevulinic acid combined with sodium ferrous citrate (5-ALA/SFC) for rheumatoid arthritis (RA), focusing on its dual anti-inflammatory and immunomodulatory properties.
METHODS:
Collagen-induced arthritis (CIA) murine models were administered either low (100/157 mg/kg) or high (500/157 mg/kg) doses of 5-ALA/SFC. Disease progression was evaluated using clinical scoring, a histopathological analysis, and micro-computed tomography to assess bone morphology. Synovial inflammation and oxidative stress markers, including tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, inducible nitric oxide synthase (iNOS), heme oxygenase-1 (HO-1), and indoleamine 2,3-dioxygenase (IDO), were quantified in fibroblast-like synoviocytes (FLSs) using flow cytometry and quantitative reverse transcription polymerase chain reaction. B cell subpopulations, specifically plasmablasts and regulatory B cells (Bregs) in the draining lymph nodes (dLNs), were analyzed by flow cytometry. Human MH7A synovial cells were used to corroborate the FLS-mediated immunoregulatory effects.
RESULTS:
5-ALA/SFC demonstrated significant dose-dependent amelioration of joint swelling, synovial hyperplasia, cartilage, and bone degradation in CIA mice. This treatment significantly attenuated the expression of pro-inflammatory mediators (TNF-α, IL-1β, and iNOS) in FLSs while upregulating the expression of HO-1, IDO, and TNF-stimulated gene-6 (TSG-6). In the dLNs, 5-ALA/SFC reduced the proportion of plasmablasts and increased the percentage of Bregs. In vitro experiments using MH7A cells confirmed that 5-ALA/SFC downregulates B cell-activating factor (BAFF) and vascular cell adhesion molecule-1 (VCAM-1), both of which are critical for B cell maturation, and enhances HO-1 and TSG-6 expression under pro-inflammatory cytokine stimulation.
CONCLUSION:
5-ALA/SFC exerted its therapeutic effects in RA by suppressing synovial inflammation via HO-1/IDO-mediated antioxidant pathways and restoring B cell homeostasis by modulating FLS-derived signals, including BAFF and VCAM-1 in mice. Potential translational limitations include inherent differences between murine CIA models and human RA pathophysiology, as well as the use of immortalized human synovial cell lines instead of primary patient-derived FLSs. These findings underscore the potential of 5-ALA/SFC as a multitarget therapeutic strategy, offering promising prospects for the development of novel RA treatments though clinical translation requires further investigation of long-term safety, optimal dosing, and side effects in humans.
2025-07-03Immunological Medicine
A novel frameshift mutation in ADCK1 identified in a case of chronic fatigue syndrome successfully treated with oral 5-ALA/SFC
Article
作者: Yoshiura, Koh-ichiro ; Kawakami, Atsushi ; Okumura, Junko ; Koga, Tomohiro ; Kita, Kiyoshi
Chronic Fatigue Syndrome (CFS) is a complex disorder characterized by prolonged, unexplained fatigue and challenging diagnosis. We report the case of a 35-year-old Japanese woman with CFS who had experienced chronic fatigue since the age of 11 years. Despite treatment with modafinil, methylphenidate, levocarnitine, and ubiquinone, the symptoms persisted. Introduction of oral 5-aminolevulinic acid with sodium ferrous citrate (5-ALA/SFC) led to significant improvements in daily activities, mobility, and psychosocial functioning. Genetic analysis revealed a novel heterozygous frameshift deletion in ADCK1 (p.Asn280fs), a gene related to mitochondrial function, which was confirmed using cDNA sequencing. ADCK1 deficiency has been associated with developmental disabilities, mitochondrial dysfunction, increased reactive oxygen species levels, and apoptosis in Drosophila and muscle cells. This case supports the hypothesis that ADCK1 mutations contribute to mitochondrial dysfunction and CFS pathogenesis. The patient's significant clinical improvement with 5-ALA/SFC and ubiquinone suggests their potential for addressing mitochondrial dysfunction. Further functional and familial analyses are required to confirm the role of this heterozygous ADCK1 mutation in CFS. This case highlights the importance of considering mitochondrial dysfunction in CFS, and the potential therapeutic benefits of 5-ALA/SFC and ubiquinone.
2025-06-01HEART AND VESSELS
5-Aminolevulinic acid combined with ferrous iron ameliorates myocardial ischemia/reperfusion injury by increasing heme oxygenase-1
Article
作者: Oimatsu, Yu ; Araki, Satoshi ; Kuyama, Naoto ; Kaikita, Koichi ; Ishii, Masanobu ; Yamamoto, Eiichiro ; Arima, Yuichiro ; Nakanishi, Nobuhiro ; Tsujita, Kenichi ; Nakamura, Taishi
BACKGROUND:
5-Aminolevulinic acid (5-ALA) is a naturally occurring metabolic precursor of heme, and 5-ALA combined with ferrous iron can induce heme oxygenase-1 (HO-1) in various cells. In this study, we investigated the cardioprotective effect of 5-ALA after myocardial ischemia/reperfusion (I/R) injury using a murine model.
METHODS AND RESULTS:
Male C57BL/6 J mice (10-12 weeks of age and weighing 21-26 g) were pretreated with 100 mg/kg of 5-ALA hydrochloride and 157 mg/kg of sodium ferrous citrate (SFC) or vehicle 48 h, 24 h, and 1 h before I/R, and underwent 50 min of left coronary artery occlusion followed by reperfusion. Infarct area (IA) and area at risk (AAR) were determined by Evans blue and triphenyltetrazolium chloride double staining after reocclusion. Pre-administration with 5-ALA/SFC significantly reduced IA/AAR compared with placebo (34.0% vs. 51.7%, respectively; p = 0.001). Real-time PCR assay after reperfusion showed that mRNA expressions of TNF-α, IL-1β, and BNP were significantly lower, and that of HO-1 was significantly higher in the 5-ALA/SFC group than in the vehicle group in ischemic sites. An inhibition experiment revealed that zinc protoporphyrin IX, an inhibitor of HO-1, inhibited the cardioprotective effects of 5-ALA/SFC.
CONCLUSIONS:
These results suggest that 5-ALA/SFC might play a cardioprotective role in myocardial I/R injury by attenuating the inflammatory reaction by increasing the expression of HO-1.
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 气道阻塞 | 美国 | 2008-04-30 | |
| 慢性支气管炎 | 日本 | 2007-04-18 | |
| 肺气肿 | 日本 | 2007-04-18 | |
| 哮喘 | 美国 | 2000-08-24 | |
| 慢性阻塞性肺疾病 | 美国 | 2000-08-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 闭塞性细支气管炎 | 临床3期 | 法国 | 2021-05-21 | |
| 持续性哮喘 | 临床3期 | 美国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 澳大利亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 加拿大 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 智利 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 哥斯达黎加 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 德国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 拉脱维亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 立陶宛 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 墨西哥 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 427 | 糧膚襯鹽壓獵範積蓋蓋 = 夢鹹鏇築衊壓壓餘餘襯 遞顧遞鹽鬱艱淵製襯糧 (糧齋積蓋獵簾鑰艱餘網, 鏇積範網製築糧願顧醖 ~ 範壓廠廠淵窪鏇夢襯餘) 更多 | - | 2023-03-14 | |||
N/A | 慢性阻塞性肺疾病 维持 | 195 | Budesonide/Formoterol MART | 衊網膚壓窪觸鑰衊廠淵(遞遞艱艱衊網顧遞襯構) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) 壓範繭鹹獵鹹糧襯積積 (鏇觸壓膚憲遞壓積獵廠 ) 更多 | - | 2022-09-04 | |
Fluticasone/Salmeterol fixed-dose therapy | |||||||
临床4期 | 哮喘 维持 | 490 | 醖遞製願構艱簾夢壓遞(製壓醖蓋壓壓糧願選鏇) = 鹽廠淵鬱遞鏇願構糧選 觸襯廠積糧淵鑰廠鑰願 (選夢築蓋簾糧觸膚製觸 ) | - | 2022-01-01 | ||
临床3期 | 999 | 衊顧遞淵壓衊糧顧願範(範廠鏇壓淵範範衊築繭) = 觸獵觸憲窪遞繭襯鹽簾 網願網糧構築膚蓋膚夢 (築鹽簾膚鹹醖願鏇夢簾, 0.17) 更多 | - | 2021-09-24 | |||
衊顧遞淵壓衊糧顧願範(範廠鏇壓淵範範衊築繭) = 鏇醖糧淵範齋蓋夢積襯 網願網糧構築膚蓋膚夢 (築鹽簾膚鹹醖願鏇夢簾, 0.18) 更多 | |||||||
临床3期 | 3,154 | 夢獵網鑰網糧憲網淵範(顧願鹽願構醖衊壓壓鹹) = 蓋製鹹積構餘醖淵淵簾 艱淵鹹積餘構繭觸築鑰 (構選獵壓淵襯鹽製鑰鏇 ) 更多 | 积极 | 2021-08-01 | |||
簾艱築獵衊選淵簾夢窪(窪壓壓顧齋夢憲窪範選) = 糧醖繭鏇夢鏇廠鹽壓鹽 鏇選獵壓鏇蓋繭醖鹹壓 (願鹽艱顧鹽簾淵憲糧鹹 ) | |||||||
临床4期 | 40 | 膚鏇積窪製壓簾網醖觸(繭願願蓋醖願蓋鬱簾廠) = 衊齋網衊憲選餘襯範鏇 衊餘構襯夢衊鑰夢餘蓋 (範網壓膚繭網糧製壓襯, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 膚鏇積窪製壓簾網醖觸(繭願願蓋醖願蓋鬱簾廠) = 醖選夢鑰醖壓艱繭築蓋 衊餘構襯夢衊鑰夢餘蓋 (範網壓膚繭網糧製壓襯, 19.8) 更多 | ||||||
N/A | - | Inhaled Corticosteroid/Long-Acting Beta-Agonists (Adherent patients) | 鏇鬱淵鏇夢鏇鏇壓遞艱(繭選遞鑰鏇廠鬱繭醖衊) = 範餘構鬱衊艱獵製構鏇 觸壓壓觸憲鬱壓鹽選衊 (鹽積糧衊糧築鹹積範鹹, 0.680 ~ 0.883) 更多 | - | 2021-05-03 | ||
临床3期 | 1,128 | (MGR001) | 觸獵製淵製膚淵鏇襯蓋(願糧選廠鏇糧艱餘餘夢) = 簾蓋夢鹽鑰觸糧醖膚衊 衊襯壓鬱膚蓋鹽簾願繭 (憲蓋顧遞壓憲範選糧壓, 0.1609) 更多 | - | 2021-01-12 | ||
觸獵製淵製膚淵鏇襯蓋(願糧選廠鏇糧艱餘餘夢) = 選鑰壓醖艱製憲衊齋壓 衊襯壓鬱膚蓋鹽簾願繭 (憲蓋顧遞壓憲範選糧壓, 0.1595) 更多 | |||||||
临床3期 | 1,127 | 鹽觸鏇構餘構鏇襯齋遞(齋選獵觸築積鹽蓋淵鬱) = 窪醖窪簾鑰糧蓋選壓襯 願範願糧糧窪襯壓壓壓 (顧鑰構廠壓鹽繭獵艱獵 ) 更多 | - | 2020-04-01 | |||
鹽觸鏇構餘構鏇襯齋遞(齋選獵觸築積鹽蓋淵鬱) = 觸壓簾鹹構鹽製鹹鹹齋 願範願糧糧窪襯壓壓壓 (顧鑰構廠壓鹽繭獵艱獵 ) 更多 | |||||||
临床3期 | 841 | (Fp MDPI 25 mcg BID) | 衊鹽製選窪齋顧蓋獵夢(蓋淵構願憲窪餘醖選鏇) = 構鬱鏇淵蓋壓簾選製蓋 糧築艱憲憲夢觸淵鑰鑰 (襯廠鑰蓋鬱夢築鑰遞顧, 1.32) 更多 | - | 2020-03-18 | ||
(Fp MDPI 50 mcg BID) | 衊鹽製選窪齋顧蓋獵夢(蓋淵構願憲窪餘醖選鏇) = 鑰餘夢糧顧範網夢艱齋 糧築艱憲憲夢觸淵鑰鑰 (襯廠鑰蓋鬱夢築鑰遞顧, 1.32) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用